Source:http://linkedlifedata.com/resource/pubmed/id/17606449
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
7
|
| pubmed:dateCreated |
2007-7-3
|
| pubmed:abstractText |
The WHO classification moved CMML to myeloproliferative/myelodysplastic disorders, and defined CMML I and CMML II according to medullary and peripheral blast count. To confirm these proposals, we analyzed 266 patients with CMML I and 73 patients with CMML II. Median survival time was 20 months for CMML I, and 15 months for CMML II (p<0.005). The cumulative risk of AML evolution differed between patient groups (p=0,001). No conclusive differences in clinical, morphologic, hematologic or cytogenetic parameters were found. These data support the WHO proposals for the classifi-cation of CMML.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jul
|
| pubmed:issn |
1592-8721
|
| pubmed:author |
pubmed-author:AulCarloC,
pubmed-author:BennettJohn MJM,
pubmed-author:GattermannNorbertN,
pubmed-author:GermingUlrichU,
pubmed-author:GiagounidisAristotelesA,
pubmed-author:HaasRainerR,
pubmed-author:HildebrandtBarbaraB,
pubmed-author:KnippSabineS,
pubmed-author:KuendgenAndreaA,
pubmed-author:StruppCorinnaC
|
| pubmed:issnType |
Electronic
|
| pubmed:volume |
92
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
974-7
|
| pubmed:meshHeading | |
| pubmed:year |
2007
|
| pubmed:articleTitle |
Chronic myelomonocytic leukemia in the light of the WHO proposals.
|
| pubmed:affiliation |
Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Düsseldorf, Germany. germing@med.uni-duesseldorf.de
|
| pubmed:publicationType |
Journal Article
|